On September 26th, Friends of Cancer Research hosted, “Future in Focus: Digital Pathology in Oncology Drug Development,” a virtual public meeting to discuss the opportunities, challenges, and promises of digital and computational pathology in oncology drug development.
On September 11, 2023 Friends of Cancer Research hosted a public meeting, “Supporting the Use of RWD in Oncology Drug Development”, in Washington, DC. The meeting included a presentation of findings from the Friends Real-world Response (rw-Response) Pilot and two panel discussions focused on the regulatory implications for use of RWD and RWE in oncology drug development.
On July 11, 2023, Friends of Cancer Research hosted, “Establishing Evidence: New Advancements Using ctDNA”, a public meeting in Washington DC. The meeting included data readouts for two initiatives: 1) the Baseline circulating tumor DNA (ctDNA) Project and 2) the ctMoniTR Step 2 Module 1 data.
On Monday, May 22, Friends of Cancer Research (Friends) hosted a hybrid public meeting titled “The Next Generation of Cellular Therapies: A Blueprint to Accelerate Development.” This meeting built on Friends’ previous work on Cell & Gene Therapies and was the second of two meetings in 2023 to explore next steps in the field.
On Wednesday, March 8, Friends of Cancer Research (Friends) hosted a virtual meeting titled “The Next Generation of Cellular Therapies: Opportunities to Accelerate Development.” This meeting sets the stage for a meeting on May 22 in Washington DC by providing context around the current state of the science and progress in cell therapy development. These…
On Thursday, November 17, Friends of Cancer Research (Friends) was proud to host our 15th Annual Meeting to address critical issues in the development of new oncology drugs. After our last two Annual Meetings were hosted virtually, we welcomed attendees back safely in-person and virtually. The entire event can be viewed here and a summary…
On March 29th, Friends of Cancer Research (Friends) convened a virtual meeting to discuss the use of multi-cancer early detection (MCED) screening tests, a promising technology that may support earlier detection of cancers. Dr. Ellen Sigal, Friends’ chair and founder, opened the meeting by highlighting the potential for MCED screening tests to shift the trajectory…
On Tuesday, February 22, 2022, Friends of Cancer Research (Friends) hosted a live virtual event that brought together leading voices from various health sectors to discuss key considerations for developing diagnostics tests for rare populations of patients, including those with rare diseases and rare biomarkers. The meeting covered topics surrounding the findings from a recent…
On Monday, September 20th, 2021, Friends of Cancer Research (Friends) hosted a virtual event that brought together industry experts, the U.S. FDA, and patient advocates to discuss improving the Breakthrough Therapy designation (BTD) program. The panelists outlined opportunities to enhance the existing expedited drug development programs, including specific recommendations for the BTD, as outlined in…
On July 29th, 2021, Friends of Cancer Research (Friends) hosted a virtual meeting revolving around the recently released 21st Century Cures 2.0 discussion draft. It featured a discussion panel of Representative Diana DeGette (D-CO), Representative Fred Upton (R-MI), Dr. Ned Sharpless, Director of the National Cancer Institute, and Dr. Richard Pazdur, Director of the Oncology…
